The modern landscape of oncology and molecular imaging is undergoing a profound transformation, driven largely by the clinical promise of…
Read More
FDA Approves Asahi Kasei Therapeutics Hovilpri for Refractory Mucocutaneous Herpes Simplex Virus in Immunocompromised Adults
The United States Food and Drug Administration (FDA) has granted formal marketing approval for Hovilpri (pritelivir) 100mg tablets, developed by…
Read More
Teva Pharmaceutical Industries Secures FDA Approval for Weltruza, a Once-Monthly Injectable Olanzapine to Transform Schizophrenia Care
The landscape of neuropsychiatric care has reached a significant milestone following the United States Food and Drug Administration (FDA) approval…
Read More
FDA Approves Pfizer’s Tukysa Regimen as Frontline Maintenance Therapy for Advanced HER2-Positive Breast Cancer
The United States Food and Drug Administration (FDA) has granted regulatory approval to Pfizer’s targeted oncology medication Tukysa (tucatinib) in…
Read More
Pharma commercial vendor selection still runs on word of mouth and a Harvard MBA student aims to change that with Rx Almanac.
For pharmaceutical companies navigating the high-stakes transition from clinical development to commercial launch, the landscape of service providers remains remarkably…
Read More
Biohaven and Ono Pharmaceutical Forge Up to $100m Licensing Deal for Advanced IgG Degrader Portfolio in Asia
The global biopharmaceutical landscape witnessed a significant strategic alliance as Biohaven Ltd. announced a landmark licensing and regional partnership agreement…
Read More
Bio-Techne Corporation Expands Global Cell Therapy Capabilities With New GMP Small Molecule Manufacturing Facility in Bristol
Life science tools and diagnostics provider Bio-Techne Corporation has officially opened a state-of-the-art, purpose-built manufacturing facility in Bristol, United Kingdom,…
Read More
Roche Secures FDA Approval for Tecentriq in Stage III dMMR Colon Cancer Setting to Establish New Treatment Paradigm
The pharmaceutical landscape for gastrointestinal oncology has undergone a significant transformation following a landmark regulatory decision by the US Food…
Read More
Alphabet and Meta now spend nearly as much on R&D as pharma’s 10 largest drugmakers
The landscape of global research and development is undergoing a seismic shift as the financial muscle of Big Tech begins…
Read More
AI-Driven Oncology Pioneer Iambic Therapeutics Targets $135m Nasdaq IPO in Banner Year for Biotech Listings
Iambic Therapeutics, an oncology-focused biotechnology company recognized for its pioneering intersection of artificial intelligence and drug discovery, has officially set…
Read More
